Xu Wenxiu, Hua Yuting, Deng Fei, Wang Dandan, Wu Yang, Zhang Wei, Tang Jinhai
Department of General Surgery, the First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Department of Gastroenterology, Wuxi People's Hospital Affiliated to Nanjing Medical University, Wuxi, China.
Cancer Sci. 2020 Sep;111(9):3122-3131. doi: 10.1111/cas.14517. Epub 2020 Jul 8.
MircoRNA (miRNA) are a group of small, non-coding, regulatory RNA with an average length of approximately 22 nucleotides, which mostly modulate gene expression post-transcriptionally through complementary binding to the 3'-untranslated region (3'-UTR) of multiple target genes. Emerging evidence has shown that miRNA are frequently dysregulated in a variety of human malignancies. Among them, microRNA-145 (miR-145) has been increasingly identified as a critical suppressor of carcinogenesis and therapeutic resistance. Resistance to tumor therapy is a challenge in cancer treatment due to the daunting range of resistance mechanisms. We reviewed the status quo of recent advancements in the knowledge of the functional role of miR-145 in therapeutic resistance and the tumor microenvironment. It may serve as an innovative biomarker for therapeutic response and cancer prognosis.
微小RNA（miRNA）是一类小的、非编码的调节性RNA，平均长度约为22个核苷酸，其大多通过与多个靶基因的3'-非翻译区（3'-UTR）互补结合，在转录后调节基因表达。新出现的证据表明，miRNA在多种人类恶性肿瘤中经常失调。其中，微小RNA-145（miR-145）越来越被认为是致癌作用和治疗耐药性的关键抑制因子。由于耐药机制繁多，肿瘤治疗耐药是癌症治疗中的一项挑战。我们综述了miR-145在治疗耐药性和肿瘤微环境中的功能作用的最新研究进展现状。它可能作为治疗反应和癌症预后的一种创新生物标志物。
